Shoreline Biosciences Stock

shorelinebio.comHealthcare / BioTech & PharmaFounded: 2020Funding to Date: $186MM

Shoreline Biosciences is a biotechnology company focused on immunotherapies for patients who are ill. Their core focus is on induced Pluripotent Stem Cells (iPSCs) and Macrophages (iMACs) which aim to target tumor and cancer cells. Shoreline Biosciences was founded in 2020 by Dan Kaufman, Kleanthis Xanthopoulos Ph.D, and Steven Holtzman and is headquartered in San Diego, CA.

Register To Buy and Sell Shares

For more details on financing and valuation for Shoreline Biosciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Shoreline Biosciences’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Shoreline Biosciences.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Shoreline Biosciences investors also invested in these private companies

Team

Management Team

Vanessa Jacoby
Chief Financial Officer
Robert Hollingsworth Ph.D
Chief Scientific Officer
Scott Forrest Ph.D
Chief Business Officer
Mauro Avanzi
Chief Medical Officer
Chuck Calderaro III
Chief Technical Officer
Kleanthis Xanthopoulos Ph.D
Chief Executive Officer & Chairman

Board Members

Christopher Fuglesang Ph.D
Boxer Capital
Frank Yu
Ally Bridge Group
Simos Simeonidis Ph.D
Ally Bridge Group

Frequently Asked Questions About Shoreline Biosciences’ Stock

plusminus
Can you buy Shoreline Biosciences’ stock?
Shoreline Biosciences is not publicly traded on NYSE or NASDAQ in the U.S. To buy Shoreline Biosciences’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Shoreline Biosciences’ stock?
Yes, you can sell stock of a private company like Shoreline Biosciences. Forge can help you sell your Shoreline Biosciences stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Shoreline Biosciences’ stock price?
Shoreline Biosciences is a privately held company and therefore does not have a public stock price. However, you may access Shoreline Biosciences’ private market stock price with Forge Data.
plusminus
What is Shoreline Biosciences’ stock ticker symbol?
Shoreline Biosciences does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Pfizer cancer vaccine science chief poached by Gilead-backed Shoreline Biosciences
Shoreline Biosciences has poached the leader of Pfizer's cancer vaccines unit, Robert Hollingsworth, Ph.D., to serve as chief scientific officer for the startup, which has recently beefed up its leadership, financing and partnerships.
Updated on: Feb 21, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.